top of page

HRMY

Harmony Biosciences Holdings Inc

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$307.8M

Burn Rate (Qtr)

N/A

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q3 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

HRMY

BPIQ_Logo_RGB-01.jpg

Company Profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Recent Posts

See what the community is saying - click to see full post.

J.P. Morgan 2023 Healthcare Conference

Q1 '22 Perceptive Closed Positions (hedge fund)

J.P. Morgan Healthcare Conference

bottom of page